Search Results - "Favalli, E G"

Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA by Iannone, F., Ferraccioli, G., Sinigaglia, L., Favalli, E. G., Sarzi-Puttini, P., Atzeni, F., Gorla, R., Bazzani, C., Govoni, M., Farina, I., Gremese, E., Carletto, A., Giollo, A., Galeazzi, M., Foti, R., Bianchino, L., La Grasta, L., Lapadula, G.

“…To assess the long-term effectiveness and safety of tocilizumab, abatacept, and tumor necrosis factor-α inhibitors (TNFi), in the Italian real-world setting of…”
Get full text

Is there really room for anti-rheumatic drugs in the treatment of COVID-19? by Favalli, EG, Ingegnoli, F, Biggioggero, M, Caporali, R

Get full text

Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy by FAVALLI, E. G, MARCHESONI, A, COLOMBO, G. L, SINIGAGLIA, L

“…The aim of this study was to retrospectively examine the pattern of utilization in clinical practice and the costs of therapy of infliximab in the treatment of…”
Get full text

Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy by FAVALLI, E. G, VARENNA, M, SINIGAGLIA, L

“…Agranulocytosis is a disorder characterized by a severe decrease in the number of granulocytes in blood, that frequently occurs as an adverse reaction to some…”
Get full text

Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients by Ferrito, M, Cincinelli, G, Manara, M, Di Taranto, R, Favalli, E G, Caporali, R

“…The objective of this study was to evaluate biological disease-modifying anti-rheumatic drugs (bDMARDs) survival in several therapy courses of patients…”
Get full text

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis by Favalli, E G, Sinigaglia, L, Varenna, M, Arnoldi, C

“…After introduction of infliximab for the treatment of rheumatoid arthritis (RA), there have been many reports of patients developing asymptomatic higher rate…”
Get full text

Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN) by Sarzi-Puttini, P, Antivalle, M, Marchesoni, A, Favalli, E G, Gorla, R, Filippini, M, Caporali, R, Bobbio-Pallavicini, F, Montecucco, C, Atzeni, F

“…Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and bone damages, which consist of joint destruction. Clinical…”
Get full text

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy by Degli Esposti, Luca, Favalli, Ennio Giulio, Sangiorgi, Diego, Di Turi, Roberta, Farina, Giuseppina, Gambera, Marco, Ravasio, Roberto

“…The aim of this analysis was to provide an estimate of drug utilization indicators (persistence, switch rate and drug consumption) on biologics and the…”
Get full text

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies by Favalli, Ennio Giulio, Biggioggero, Martina, Marchesoni, Antonio, Meroni, Pier Luigi

“…The aim of this study was to evaluate the survival on treatment with second-line biologic therapy in RA patient non-responders to TNF inhibitors (TNFis) by…”
Get full text

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry by Manara, Maria, Caporali, Roberto, Favalli, Ennio G, Grosso, Vittorio, Atzeni, Fabiola, Sarzi Puttini, Piercarlo, Gorla, Roberto, Bazzani, Chiara, Fusaro, Enrico, Pellerito, Raffaele, Rocchetta, Pier Andrea, Sinigaglia, Luigi

“…We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre…”
Get full text

Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting by Iannazzo, Sergio, Benucci, Maurizio, Favalli, Ennio Giulio

“…Switching to a different mechanism of action in rheumatoid arthritis (RA) patients after a first anti-TNF-α has proved to be effective. The objective of this…”
Get full text

The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease by Lubrano, E., Armuzzi, A., Scriffignano, S., Felice, C., Perrotta, F.M., Venerito, V., Del Vescovo, S., Ramonda, R., Cassone, G., Atzeni, F., Caporali, R., Conti, F., Gremese, E., Iannone, F., Sebastiani, M., Favalli, E.G.

“…Objective. To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with…”
Get full text

Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-α blockade by Ingegnoli, Francesca, Fantini, Flavio, Favalli, Ennio Giulio, Soldi, Amedeo, Griffini, Samantha, Galbiati, Valentina, Meroni, Pier Luigi, Cugno, Massimo

“…Abstract Objective Increased cardiovascular (CV) risk is a rheumatoid arthritis (RA) hallmark and it has been mainly related to chronic systemic inflammation…”
Get full text

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) by Scarpato, Salvatore, Antivalle, Marco, Favalli, Ennio G., Nacci, Francesca, Frigelli, Sabrina, Bartoli, Francesca, Bazzichi, Laura, Minisola, Giovanni, Matucci Cerinic, Marco

“…Objective. To identify the determinants of anti-TNF-naive patients’ preferences for the route of administration of anti-TNF agents. Methods. The study was…”
Get full text

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries by Codullo, Veronica, Iannone, Florenzo, Sinigaglia, Luigi, Favalli, Ennio Giulio, Sarzi-Puttini, Piercarlo, Atzeni, Fabiola, Ferraccioli, Gianfranco, Gremese, Elisa, Carletto, Antonio, Giollo, Alessandro, Govoni, Marcello, Bergossi, Francesca, Galeazzi, Mauro, Cantarini, Luca, Salaffi, Fausto, Di Carlo, Marco, Bazzani, Chiara, Pellerito, Raffaele, Sebastiani, Marco, Ramonda, Roberta, Lapadula, Giovanni, Caporali, Roberto

“…Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outcomes in rheumatoid arthritis (RA). They are widely used in…”
Get full text

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection by Biggioggero, Martina, Crotti, Chiara, Becciolini, Andrea, Favalli, Ennio Giulio

“…Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by articular and systemic manifestations, such as anemia, fatigue, osteoporosis, and…”
Get full text

Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety by Favalli, Ennio G, Caporali, Roberto, Sinigaglia, Luigi, Pipitone, Nicolo', Miniati, Irene, Montecucco, Carlomaurizio, Matucci-Cerinic, Marco

“…Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific…”
Get full text

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis by Raimondo, Maria Gabriella, Biggioggero, Martina, Crotti, Chiara, Becciolini, Andrea, Favalli, Ennio Giulio

“…In recent years the use of biotechnological agents has drastically revolutionized the therapeutic approach and the progression of rheumatoid arthritis (RA). In…”
Get full text

Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years by Iannone, Florenzo, Salaffi, Fausto, Marchesoni, Antonio, Gorla, Roberto, Atzeni, Fabiola, Govoni, Marcello, Gremese, Elisa, Lapadula, Giovanni, On Behalf Of Gisea Gruppo Italiano di Studio Sulle Early Arthritides, A

“…To assess long-term drug survival and effectiveness in biological drug-naïve patients with rheumatoid arthritis (RA), starting infliximab as first treatment,…”
Get full text

PMS41 - Tocilizumab after A First-Line with Anti-Tnf in Rheumatoid Arthritis: A Cost-Consequence Analysis in the Italian Setting by Iannazzo, S, Benucci, M, Favalli, EG

Get full text